| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A315 Addressing Biased Survival Due To Crossover in Trials
|
Morgan, GJ
|
|
2009
|
9 |
S1 |
p. S50-S51
2 p.
|
artikel
|
| 2 |
A418 AL Amyloidosis with IgM Monoclonal Protein
|
Palladini, G
|
|
2009
|
9 |
S1 |
p. S66-
1 p.
|
artikel
|
| 3 |
A627 Alternate Splicing Is Frequently Observed in Myeloma and Has Impact on Clinical Outcome
|
Amin, SB
|
|
2009
|
9 |
S1 |
p. S93-
1 p.
|
artikel
|
| 4 |
A450 Alternating VAMP/ThaCyDex: An Effective Salvage Regimen in Relapsed Multiple Myeloma Patients
|
Colado, E
|
|
2009
|
9 |
S1 |
p. S72-S73
2 p.
|
artikel
|
| 5 |
A115 Amifostine to Reduce the Toxicity of Outpatient ASCT in Multiple Myeloma
|
Scortechini, I
|
|
2009
|
9 |
S1 |
p. S18-
1 p.
|
artikel
|
| 6 |
A318 An Analysis of the Charges Associated with Peripheral Blood Hematopoietic Progenitor Cell (HPC)
|
Hosing, C
|
|
2009
|
9 |
S1 |
p. S51-
1 p.
|
artikel
|
| 7 |
A316 A New Method of Response Assessment in AL Amyloidosis Using NT-ProBNP with Hematologic Response
|
Wechalekar, A
|
|
2009
|
9 |
S1 |
p. S51-
1 p.
|
artikel
|
| 8 |
A567 A NFKB1 Polymorphism Improves Effect of IFN-alfa Maintenance Treatment of Myeloma Patients After ASCT
|
Vangsted, AJ
|
|
2009
|
9 |
S1 |
p. S86-
1 p.
|
artikel
|
| 9 |
A105 A Phase III Study of MEL200 Versus MEL100 in Newly Diagnosed Myeloma Young Patients
|
Boccadoro, M
|
|
2009
|
9 |
S1 |
p. S16-
1 p.
|
artikel
|
| 10 |
A117 A Phase III Study of VMPT Versus VMP in Newly Diagnosed Elderly Myeloma Patients
|
Palumbo, A
|
|
2009
|
9 |
S1 |
p. S19-
1 p.
|
artikel
|
| 11 |
A204 A Phase III Trial of Kyphoplasty Versus Nonsurgical Care for Cancer Patients with Vertebral Fractures
|
Berenson, JR
|
|
2009
|
9 |
S1 |
p. S33-S34
2 p.
|
artikel
|
| 12 |
A133 A Pilot Feasibility Study of Home Administration of Bortezomib to Patients with Relapsed Myeloma
|
Hammond, L
|
|
2009
|
9 |
S1 |
p. S21-
1 p.
|
artikel
|
| 13 |
A235 A Prolonged Therapy Improves Quality of Response, and CR Associated with Superior Outcomes, with VMP
|
Harousseau, JL
|
|
2009
|
9 |
S1 |
p. S40-
1 p.
|
artikel
|
| 14 |
A364 A Randomized Phase I Study of Melphalan and Bortezomib for Autologous Transplant in Myeloma
|
Kaufman, JL
|
|
2009
|
9 |
S1 |
p. S60-
1 p.
|
artikel
|
| 15 |
A165 Are TBI-Based Conditioning Regimens Better for Obese Patients Receiving Autotransplants for Myeloma?
|
Hari, PN
|
|
2009
|
9 |
S1 |
p. S28-S29
2 p.
|
artikel
|
| 16 |
A586 A Slow Pattern of Response in a Relapsed Multiple Myeloma Patient Treated with Lenalidomide
|
Ramirez, G
|
|
2009
|
9 |
S1 |
p. S88-S89
2 p.
|
artikel
|
| 17 |
A630 Autoimmune Thrombocytopenia After Autologous Stem Cell Transplantation in a Case of Multiple Myeloma
|
Izumi, T
|
|
2009
|
9 |
S1 |
p. S94-
1 p.
|
artikel
|
| 18 |
A251 Better Efficacy/Toxicity Ratio of Velcade-Based Regimens
|
Hajek, R
|
|
2009
|
9 |
S1 |
p. S44-S45
2 p.
|
artikel
|
| 19 |
A167 BMP6: A Novel Antiangiogenic, Antiproliferative, and Prognostic Factor Expressed by Myeloma Cells
|
Seckinger, A
|
|
2009
|
9 |
S1 |
p. S29-
1 p.
|
artikel
|
| 20 |
A068 Bone Marrow Renin-Angiotensin System in Multiple Myeloma
|
Saka, B
|
|
2009
|
9 |
S1 |
p. S10-
1 p.
|
artikel
|
| 21 |
A006 Bortezomib Alone and PAD in Multiple Myeloma
|
Kraj, MA
|
|
2009
|
9 |
S1 |
p. S3-
1 p.
|
artikel
|
| 22 |
A220 Bortezomib and Melphalan as Part of VMP Are Associated with Similar Hematologic Toxicity to MP Alone
|
Richardson, PG
|
|
2009
|
9 |
S1 |
p. S36-S37
2 p.
|
artikel
|
| 23 |
A334 Bortezomib-Based Therapy Following Prior Lenalidomide + Dexamethasone in Relapsed Multiple Myeloma
|
Trieu, Y
|
|
2009
|
9 |
S1 |
p. S53-S54
2 p.
|
artikel
|
| 24 |
A385 Bortezomib-Based Therapy Induces Better Outcomes of Autologous Stem Cell Tranaplantation in Myeloma
|
Kim, SJ
|
|
2009
|
9 |
S1 |
p. S63-
1 p.
|
artikel
|
| 25 |
A247 Bortezomib, Dexamethasone, Cyclophosphamide, Lenalidomide (VDCR) Has High Efficacy in First-Line MM
|
Kumar, S
|
|
2009
|
9 |
S1 |
p. S43-S44
2 p.
|
artikel
|
| 26 |
A512 Bortezomib, Doxorubicin, and Dexamethasone (PAD) Combination Therapy Followed by Thalidomide and Dex
|
Lee, SS
|
|
2009
|
9 |
S1 |
p. S80-
1 p.
|
artikel
|
| 27 |
A230 Bortezomib in Real Patients: A Single-Center Experience
|
Percy, LA
|
|
2009
|
9 |
S1 |
p. S38-S39
2 p.
|
artikel
|
| 28 |
A382 Bortezomib in Relapsed/Refractory Multiple Myeloma
|
Shen, Z
|
|
2009
|
9 |
S1 |
p. S62-
1 p.
|
artikel
|
| 29 |
A135 Bortezomib International Observational Study in Multiple Myeloma: Baseline Characteristics
|
Zervas, K
|
|
2009
|
9 |
S1 |
p. S22-
1 p.
|
artikel
|
| 30 |
A426 Bortezomib or Lenalidomide to Treat Disease Relapse After Allogeneic Transplantation in Myeloma
|
Montefusco, V
|
|
2009
|
9 |
S1 |
p. S68-
1 p.
|
artikel
|
| 31 |
A383 Bortezomib plus Thalidomide in Newly Diagnosed Myeloma
|
Chen, S
|
|
2009
|
9 |
S1 |
p. S62-S63
2 p.
|
artikel
|
| 32 |
A154 Bortezomib (Velcade)/Melphalan/Prednisone (VMP) Versus Velcade/Thalidomide/Prednisone (VTP) in Elderly
|
Mateos, MV
|
|
2009
|
9 |
S1 |
p. S25-
1 p.
|
artikel
|
| 33 |
A255 2CdA and Rituximab Combination Treatment for Patients with Waldenström: Results of a Multicenter Study
|
Laszlo, D
|
|
2009
|
9 |
S1 |
p. S45-
1 p.
|
artikel
|
| 34 |
A009 CD44 and CD138 Expression on CD45-Low Myeloma Cells
|
Kraj, MA
|
|
2009
|
9 |
S1 |
p. S4-
1 p.
|
artikel
|
| 35 |
A486 CD138-Selected Myeloma FISH Panel Is a Sensitive Indicator of Minimal Residual Disease and Can Reveal High-Risk DNA Mutations
|
Hofmeister, CC
|
|
2009
|
9 |
S1 |
p. S77-
1 p.
|
artikel
|
| 36 |
A036 CDT Consolidation Following ASCT is Safe and Well Tolerated and Improves Depth of Response
|
Rabin, NK
|
|
2009
|
9 |
S1 |
p. S7-S8
2 p.
|
artikel
|
| 37 |
A423 CD138, VEGF and CD34 Immunohistochemical Expression in LPL: Correlations with Clinical Data
|
Tzenou, T
|
|
2009
|
9 |
S1 |
p. S67-
1 p.
|
artikel
|
| 38 |
A162 Changes in M-Protein at Multiple Myeloma Relapse
|
Hobbs, JA
|
|
2009
|
9 |
S1 |
p. S27-
1 p.
|
artikel
|
| 39 |
A530 Characterization of Bortezomib Resistance in Multiple Myeloma Cell Lines
|
Al Shabeeb, AH
|
|
2009
|
9 |
S1 |
p. S81-S82
2 p.
|
artikel
|
| 40 |
A369 Clinical and Biological Features of Biclonal Gammopathies: A Review of 203 Cases
|
Decaux, O
|
|
2009
|
9 |
S1 |
p. S60-S61
2 p.
|
artikel
|
| 41 |
A140 Clinical and Immunologic Evaluation of Zoledronate-Activated γδ T-Cell—Based Immunotherapy of Myeloma
|
Suzuki, K
|
|
2009
|
9 |
S1 |
p. S23-
1 p.
|
artikel
|
| 42 |
A522 Clinical Efficacy of Velcade/CTD Regimen in Patients with Relapsed or Refractory Multiple Myeloma
|
Kim, YK
|
|
2009
|
9 |
S1 |
p. S81-
1 p.
|
artikel
|
| 43 |
A449 Clinical Features and Treatment Outcomes of AL Amyloidosis in Korea
|
Kim, SJ
|
|
2009
|
9 |
S1 |
p. S72-
1 p.
|
artikel
|
| 44 |
A607 Clinical Implication of Hyperdiploidy/Non-Hyperdiploidy in MM Patients Treated by Newer Drugs
|
Smetana, J
|
|
2009
|
9 |
S1 |
p. S89-
1 p.
|
artikel
|
| 45 |
A433 Comparison of Serum Cytokines with Prognostic Impact in MM
|
Maltezas, D
|
|
2009
|
9 |
S1 |
p. S69-
1 p.
|
artikel
|
| 46 |
A504 Consolidation Therapy with Thalidomide Improves Survival Post ASCT
|
Bahlis, NJ
|
|
2009
|
9 |
S1 |
p. S79-
1 p.
|
artikel
|
| 47 |
A284 Cytarabine-Based Regimens for Mobilization of Peripheral Blood Stem Cells in Multiple Myeloma
|
Montefusco, V
|
|
2009
|
9 |
S1 |
p. S47-
1 p.
|
artikel
|
| 48 |
A518 Dendritic Cells Immunotherapy: A Phase II Clinical Trial
|
Zahradova, L
|
|
2009
|
9 |
S1 |
p. S80-S81
2 p.
|
artikel
|
| 49 |
A282 Dexamethasone and Adrenal Suppression in Myeloma
|
Drake, MT
|
|
2009
|
9 |
S1 |
p. S46-S47
2 p.
|
artikel
|
| 50 |
A435 Dex/Thal as Induction and Maintenance Treatment in Elderly Patients with MM: A Randomized Trial
|
Mounier, MM
|
|
2009
|
9 |
S1 |
p. S69-S70
2 p.
|
artikel
|
| 51 |
A016 Donor Versus No-Donor Analysis of Newly Diagnosed Myeloma Patients included in the HOVON-50/54 Study
|
Lokhorst, H
|
|
2009
|
9 |
S1 |
p. S5-S6
2 p.
|
artikel
|
| 52 |
A320 Effective Bortezomib-Based Therapy for IgM Myeloma in 2 Patients with Unique Cytogenetic Features
|
Willenbacher, E
|
|
2009
|
9 |
S1 |
p. S51-S52
2 p.
|
artikel
|
| 53 |
A114 Effectiveness of Lenalidomide in Patients with Relapsed or Progressive Multiple Myeloma
|
Amor, AA
|
|
2009
|
9 |
S1 |
p. S17-S18
2 p.
|
artikel
|
| 54 |
A163 Efficacy and Outcome of Autologous Transplantation in Rare Myelomas
|
Morris, T
|
|
2009
|
9 |
S1 |
p. S27-S28
2 p.
|
artikel
|
| 55 |
A425 EGFR Based on Cystatin-C, Creatinine, and Age Is Independently Associated with Survival in Myeloma
|
Dimopoulos, MA
|
|
2009
|
9 |
S1 |
p. S68-
1 p.
|
artikel
|
| 56 |
A342 Endothelial Stress Markers in Multiple Myeloma Patients
|
Richardson, PG
|
|
2009
|
9 |
S1 |
p. S55-
1 p.
|
artikel
|
| 57 |
A141 Enoxaparin Versus Aspirin Versus Low-Fixed-Dose Warfarin in MM Patients Treated Up Front with Thalidomide
|
Palumbo, A
|
|
2009
|
9 |
S1 |
p. S23-S24
2 p.
|
artikel
|
| 58 |
A217 Erythropoiesis-Stimulating Agents: No Impact on Long-Term Outcome in MM Patients in the VISTA Trial
|
Richardson, PG
|
|
2009
|
9 |
S1 |
p. S35-S36
2 p.
|
artikel
|
| 59 |
A537 Ethnicity and Myeloma: Experience of a Large UK Stem Cell Transplantation Center
|
Auner, HW
|
|
2009
|
9 |
S1 |
p. S84-
1 p.
|
artikel
|
| 60 |
A609 Extended Follow-up Results of BiRD Therapy: Prolonged Responses Achieved
|
Mark, TM
|
|
2009
|
9 |
S1 |
p. S89-S90
2 p.
|
artikel
|
| 61 |
A488 Extramedullary Disease in Multiple Myeloma: A Rare and Still Undefined Clinical Picture
|
Kortuem, M
|
|
2009
|
9 |
S1 |
p. S78-
1 p.
|
artikel
|
| 62 |
A069 FLC Removal HD Improves Outcomes in Myeloma Kidney
|
Cook, M
|
|
2009
|
9 |
S1 |
p. S10-S11
2 p.
|
artikel
|
| 63 |
A585 Flow Cytometric Determination of Circulating Plasma Cells in Newly Diagnosed Myeloma
|
Mohapatra, PN
|
|
2009
|
9 |
S1 |
p. S88-
1 p.
|
artikel
|
| 64 |
A107 Flow Cytometry Remission Is the Most Relevant Prognostic Factor for MM Patients Who Undergo ASCT
|
Miguel, J San
|
|
2009
|
9 |
S1 |
p. S16-S17
2 p.
|
artikel
|
| 65 |
A326 Free Light Chain (by rFLC) Monitoring Reveals Early Relapse After HSCT
|
Willenbacher, E
|
|
2009
|
9 |
S1 |
p. S52-
1 p.
|
artikel
|
| 66 |
A437 Frequent Amplification of IL-6 Receptor Gene in Patients with Multiple Myeloma
|
Park, HK
|
|
2009
|
9 |
S1 |
p. S70-
1 p.
|
artikel
|
| 67 |
A574 Generic Bortezomib-Induced Severe Peripheral Neuropathy in Newly Diagnosed Multiple Myeloma Patients
|
Chakrabarti, P
|
|
2009
|
9 |
S1 |
p. S86-S87
2 p.
|
artikel
|
| 68 |
A330 Hepatic Plasmacytomas as a Manifestation of Extramedullary Relapse in Multiple Myeloma
|
Fraser, L
|
|
2009
|
9 |
S1 |
p. S53-
1 p.
|
artikel
|
| 69 |
A345 High Baseline NTX Predicts for Inferior Survival and Shorter Time to First SRE in Multiple Myeloma
|
Terpos, E
|
|
2009
|
9 |
S1 |
p. S55-S56
2 p.
|
artikel
|
| 70 |
A130 Higher Incidence of Osteonecrosis of the Jaw in Patients with Multiple Myeloma Treated with Zoledron
|
de la Rubia, J
|
|
2009
|
9 |
S1 |
p. S20-S21
2 p.
|
artikel
|
| 71 |
A014 High Serum TIMP-1 Correlates with Advanced Myeloma and Poor Survival
|
Terpos, E
|
|
2009
|
9 |
S1 |
p. S5-
1 p.
|
artikel
|
| 72 |
A185 High Thrombospondin Level Correlates Closely with Poor Response to Bortezomib Treatment
|
Pour, L
|
|
2009
|
9 |
S1 |
p. S31-S32
2 p.
|
artikel
|
| 73 |
A046 HOVON-50 Final Analysis of Thalidomide Combined with Adriamycin, Dexamethasone, and HDM
|
Lokhorst, H
|
|
2009
|
9 |
S1 |
p. S8-
1 p.
|
artikel
|
| 74 |
A218 HSCT for Multiple Myeloma: An Analysis of 14 Cases
|
Fu, C
|
|
2009
|
9 |
S1 |
p. S36-
1 p.
|
artikel
|
| 75 |
A471 Hypodiploid Karyotype Is the Singlemost Adverse Prognostic Factor for Myeloma in the Bortezomib Era
|
Tan, D
|
|
2009
|
9 |
S1 |
p. S75-
1 p.
|
artikel
|
| 76 |
A013 Immunoexpression of MIP-1alpha on Marrow Biopsies Correlates with the Extent of Myeloma Bone Disease
|
Terpos, E
|
|
2009
|
9 |
S1 |
p. S4-S5
2 p.
|
artikel
|
| 77 |
A352 Impact of Complete Response on Quality of Life in Newly Diagnosed Multiple Myeloma Patients
|
Dhawan, R
|
|
2009
|
9 |
S1 |
p. S58-
1 p.
|
artikel
|
| 78 |
A554 Impaired Stem Cell Mobilization by Fludarabine in MM: Results from a Randomized Phase II Trial
|
Johnsen, HE
|
|
2009
|
9 |
S1 |
p. S85-
1 p.
|
artikel
|
| 79 |
A109 Improved Survival in Younger Patients with Multiple Myeloma: A Population-Based Study from Malmö, Sweden
|
Turesson, I
|
|
2009
|
9 |
S1 |
p. S17-
1 p.
|
artikel
|
| 80 |
A091 Incidence of Myeloma Over 56 Years (1950–2006): A Population-Based Study from Malmö, Sweden
|
Turesson, I
|
|
2009
|
9 |
S1 |
p. S14-
1 p.
|
artikel
|
| 81 |
A448 Intermittent Dex/Thal as Pretransplantation and Maintenance Treatment in De Novo MM: A Randomized Trial
|
Mounier, MM
|
|
2009
|
9 |
S1 |
p. S71-S72
2 p.
|
artikel
|
| 82 |
A224 Lenalidomide, Bortezomib, and Dexamethasone Has Notable Activity in High-Risk First-Line Myeloma
|
Richardson, PG
|
|
2009
|
9 |
S1 |
p. S38-
1 p.
|
artikel
|
| 83 |
A227 Lenalidomide, Bortezomib, and Dexamethasone Is Active in High-Risk Relapsed/Refractory Myeloma
|
Richardson, PG
|
|
2009
|
9 |
S1 |
p. S38-
1 p.
|
artikel
|
| 84 |
A611 Lenalidomide Maintenance Therapy in Patients with Multiple Myeloma
|
Fillitz, M
|
|
2009
|
9 |
S1 |
p. S90-
1 p.
|
artikel
|
| 85 |
A136 Len/Dex ± Bortezomib for Advanced Myeloma According to Prior Neuropathy: The Impact of Cytogenetics
|
Dimopoulos, MA
|
|
2009
|
9 |
S1 |
p. S22-S23
2 p.
|
artikel
|
| 86 |
A030 Long-Term Care Guidelines for Myeloma Patients
|
Moran, D
|
|
2009
|
9 |
S1 |
p. S6-S7
2 p.
|
artikel
|
| 87 |
A076 Long-Term Follow-up of Multiple Myeloma Patients Treated by VELCADE
|
Michallet, M
|
|
2009
|
9 |
S1 |
p. S11-
1 p.
|
artikel
|
| 88 |
A051 Long-Term Follow-up Results of IFM9903 and IFM9904 Trials: RIC Versus ASCT
|
Moreau, P
|
|
2009
|
9 |
S1 |
p. S8-S9
2 p.
|
artikel
|
| 89 |
A274 Long-Term Outcome After Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma
|
Montefusco, V
|
|
2009
|
9 |
S1 |
p. S46-
1 p.
|
artikel
|
| 90 |
A481 Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Smoldering or Indolent Myeloma
|
Short, KE Detweiler
|
|
2009
|
9 |
S1 |
p. S76-S77
2 p.
|
artikel
|
| 91 |
A432 Long-Term Treatment with Lenalidomide in Previously Treated Subjects with Multiple Myeloma
|
Amor, AA
|
|
2009
|
9 |
S1 |
p. S68-S69
2 p.
|
artikel
|
| 92 |
A146 Management of Anemia in Multiple Myeloma Patients with Anemia: Findings from the A.C.T. Study
|
Ludwig, H
|
|
2009
|
9 |
S1 |
p. S24-
1 p.
|
artikel
|
| 93 |
A628 MicroRNA Profile Identifies Distinct Clinically Relevant Subgroups in Multiple Myeloma
|
Sophia, A
|
|
2009
|
9 |
S1 |
p. S93-S94
2 p.
|
artikel
|
| 94 |
A355 Monoclonal Antibodies That Provide a Reliable New Assay for Serum Immunoglobulin FLC in Myeloma
|
Drayson, MT
|
|
2009
|
9 |
S1 |
p. S58-S59
2 p.
|
artikel
|
| 95 |
A300 Monoclonal Protein Detection in AL Amyloidosis Revisited: Analysis of 642 Patients
|
Wechalekar, A
|
|
2009
|
9 |
S1 |
p. S49-
1 p.
|
artikel
|
| 96 |
A116 MP versus MPT in Elderly Myeloma Patients: The Final Outcome of the HOVON-49 Study
|
Wijermans, PW
|
|
2009
|
9 |
S1 |
p. S18-S19
2 p.
|
artikel
|
| 97 |
A546 MRC Myeloma IX: Preliminary Results from The Intensive Pathway Study
|
Owen, RG
|
|
2009
|
9 |
S1 |
p. S84-S85
2 p.
|
artikel
|
| 98 |
A547 MRC Myeloma IX: Preliminary Results from the Non-Intensive Study
|
Owen, RG
|
|
2009
|
9 |
S1 |
p. S85-
1 p.
|
artikel
|
| 99 |
A479 MRD Studies in MM: Data from the MRC Myeloma IX Trial
|
Owen, RG
|
|
2009
|
9 |
S1 |
p. S76-
1 p.
|
artikel
|
| 100 |
A626 Multiple Myeloma in Black Africans: Does It Behave Differently?
|
Cécile, N
|
|
2009
|
9 |
S1 |
p. S93-
1 p.
|
artikel
|
| 101 |
A417 Multiple Myeloma Observational Study in Thai Patients
|
Siritanaratkul, N
|
|
2009
|
9 |
S1 |
p. S65-S66
2 p.
|
artikel
|
| 102 |
A475 Multiple Myeloma with Involvement of the Biliary System
|
Mele, G
|
|
2009
|
9 |
S1 |
p. S76-
1 p.
|
artikel
|
| 103 |
A177 Multiple Myeloma with Monoclonal Free IgG3 Heavy Chains and Free Kappa Light Chains
|
Pratt, G
|
|
2009
|
9 |
S1 |
p. S30-S31
2 p.
|
artikel
|
| 104 |
A629 Myeloma: 15 Years' Experience from a Major Cancer Center in India
|
Raina, V
|
|
2009
|
9 |
S1 |
p. S94-
1 p.
|
artikel
|
| 105 |
A155 Neurologic Monitoring Reduces the Incidence of Bortezomib-Induced Peripheral Neuropathy in MM
|
Petit, J
|
|
2009
|
9 |
S1 |
p. S25-S26
2 p.
|
artikel
|
| 106 |
A393 New Therapeutics and Prognosis of Multiple Myeloma After ASCT
|
Vangsted, AJ
|
|
2009
|
9 |
S1 |
p. S63-
1 p.
|
artikel
|
| 107 |
A618 Non-Frozen Autologous Peripheral Blood Stem Cells Transplantation in Multiple Myeloma
|
Belkaid, MI
|
|
2009
|
9 |
S1 |
p. S91-S92
2 p.
|
artikel
|
| 108 |
A288 Non-Myeloablative Allo-SCT for Relapsed Myeloma: A Single-Center Experience
|
Minnema, MC
|
|
2009
|
9 |
S1 |
p. S48-
1 p.
|
artikel
|
| 109 |
A621 Nonmyeloablative Conditioning and Allogeneic Transplantation for Multiple Myeloma
|
Elliott, B
|
|
2009
|
9 |
S1 |
p. S92-
1 p.
|
artikel
|
| 110 |
A191 NPI-0052: A Second-Generation Proteasome Inhibitor
|
Spear, MA
|
|
2009
|
9 |
S1 |
p. S33-
1 p.
|
artikel
|
| 111 |
A404 OPTIMUM Trial: Randomized Comparison of Thalidomide Versus Dexamethasone for Relapsed Myeloma
|
Kropff, M
|
|
2009
|
9 |
S1 |
p. S64-
1 p.
|
artikel
|
| 112 |
A120 Osteonecrosis of the Jaw in Multiple Myeloma Patients: Risk Factors of Early ONJ, Decreased Impact After 2005
|
Fuzibet, JG
|
|
2009
|
9 |
S1 |
p. S19-S20
2 p.
|
artikel
|
| 113 |
A221 Outcomes in Relapsed Multiple Myeloma in the United Kingdom
|
Gaugris, S
|
|
2009
|
9 |
S1 |
p. S37-
1 p.
|
artikel
|
| 114 |
A422 Outcomes of Stem Cell Transplantation for Myeloma in Thailand
|
Lawasut, P
|
|
2009
|
9 |
S1 |
p. S66-S67
2 p.
|
artikel
|
| 115 |
A088 Overall Survival Among Patients with Multiple Myeloma (MM) Treated with Zoledronic Acid (ZOL)
|
Berenson, JR
|
|
2009
|
9 |
S1 |
p. S12-S13
2 p.
|
artikel
|
| 116 |
A097 PAD-MEL100-LP-L in Elderly Untreated Myeloma Patients
|
Palumbo, A
|
|
2009
|
9 |
S1 |
p. S15-S16
2 p.
|
artikel
|
| 117 |
A337 Panobinostat and Bortezomib Phase I Trial in Multiple Myeloma
|
Sezer, O
|
|
2009
|
9 |
S1 |
p. S54-
1 p.
|
artikel
|
| 118 |
A329 Panobinostat and Lenalidomide Combination Phase I Trial in Myeloma
|
Spencer, A
|
|
2009
|
9 |
S1 |
p. S52-S53
2 p.
|
artikel
|
| 119 |
A534 Perifosine: Final Results of a Phase II Trial in Relapsed/Refractory Waldenström Macroglobulinemia
|
Ghobrial, IM
|
|
2009
|
9 |
S1 |
p. S83-
1 p.
|
artikel
|
| 120 |
A134 Peripheral Neuropathy as Assessed in an International Observational Study of Bortezomib
|
Delforge, M
|
|
2009
|
9 |
S1 |
p. S21-S22
2 p.
|
artikel
|
| 121 |
A172 Peripheral Neuropathy with VMP Resolves in the Majority of Patients and Shows a Rate Plateau
|
Mateos, MV
|
|
2009
|
9 |
S1 |
p. S30-
1 p.
|
artikel
|
| 122 |
A212 Pharmacodynamics of High-Dose Melphalan in Myeloma
|
Nath, CE
|
|
2009
|
9 |
S1 |
p. S34-S35
2 p.
|
artikel
|
| 123 |
A129 Phase Ib Study of Elotuzumab (HuLuc63) inCombination with Lenalidomide in Relapsed Multiple Myeloma
|
Lonial, S
|
|
2009
|
9 |
S1 |
p. S20-
1 p.
|
artikel
|
| 124 |
A333 Phase I/II Trial of Cyclophosphamide, Prednisone, and Lenalidomide for Relapsed and Refractory MM
|
Reece, D
|
|
2009
|
9 |
S1 |
p. S53-
1 p.
|
artikel
|
| 125 |
A268 Phase I/II Trial of Lenalidomide, Bortezomib, Doxil, and Dexamethasone in Front-Line Multiple Myeloma
|
Jakubowiak, AJ
|
|
2009
|
9 |
S1 |
p. S45-S46
2 p.
|
artikel
|
| 126 |
A349 Phase I/II Trial of Perifosine + Bortezomib in Rel/Ref MM Patients Previously Treated with Bortezomib
|
Richardson, PG
|
|
2009
|
9 |
S1 |
p. S57-
1 p.
|
artikel
|
| 127 |
A493 Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM) (PX-171-004)
|
Vij, R
|
|
2009
|
9 |
S1 |
p. S78-
1 p.
|
artikel
|
| 128 |
A377 Phase II Study of Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (PX-171-003)
|
Jagannath, S
|
|
2009
|
9 |
S1 |
p. S61-
1 p.
|
artikel
|
| 129 |
A378 Phase II Study of Carfilzomib in Patients with Relapsed Myeloma (PX-171-004)
|
Vij, R
|
|
2009
|
9 |
S1 |
p. S61-S62
2 p.
|
artikel
|
| 130 |
A535 Phase II Trial of Bortezomib and Rituximab in Relapsed/Refractory Waldenström Macroglobulinemia
|
Ghobrial, IM
|
|
2009
|
9 |
S1 |
p. S83-S84
2 p.
|
artikel
|
| 131 |
A470 Phase II Trial of Mel/Dex + Bortezomib for AL Amyloidosis
|
Gasparetto, C
|
|
2009
|
9 |
S1 |
p. S74-S75
2 p.
|
artikel
|
| 132 |
A264 Phase I Study of Elotuzumab (HuLuc63) in Combination with Bortezomib in Relapsed Multiple Myeloma
|
Jakubowiak, AJ
|
|
2009
|
9 |
S1 |
p. S45-
1 p.
|
artikel
|
| 133 |
A573 Phase I Trial of CCI-779 and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma
|
Roccaro, AM
|
|
2009
|
9 |
S1 |
p. S86-
1 p.
|
artikel
|
| 134 |
A347 Phase I Trial of Perifosine, Lenalidomide, and Dexamethasone in Relapsed or Refractory Myeloma
|
Jakubowiak, AJ
|
|
2009
|
9 |
S1 |
p. S56-S57
2 p.
|
artikel
|
| 135 |
A090 Plasma Cell Leukemia: A SEER Database Analysis
|
Ramsingh, G
|
|
2009
|
9 |
S1 |
p. S14-
1 p.
|
artikel
|
| 136 |
A578 Plasma Cell Leukemia: A Study of 28 cases from India
|
Chopra, A
|
|
2009
|
9 |
S1 |
p. S87-
1 p.
|
artikel
|
| 137 |
A215 Post-ASCT Thalidomide Consolidation Further Prolongs PFS For Patients who Have Already Achieved A Complete Remission
|
Spencer, A
|
|
2009
|
9 |
S1 |
p. S35-
1 p.
|
artikel
|
| 138 |
A035 Predictive Features for Long Survival in Multiple Myeloma
|
Wang, M
|
|
2009
|
9 |
S1 |
p. S7-
1 p.
|
artikel
|
| 139 |
A584 Preliminary Results of a Phase I Trial of Intravenous MV-NIS for Relapsed/Refractory Multiple Myeloma
|
Tong, C
|
|
2009
|
9 |
S1 |
p. S88-
1 p.
|
artikel
|
| 140 |
A075 Preliminary Results of Bortezomib in Combination with Dexamethasone Followed by Maintenance Therapy
|
Aurelio, L
|
|
2009
|
9 |
S1 |
p. S11-
1 p.
|
artikel
|
| 141 |
A231 Prescribed Exercise in Myeloma Patients Reduces Fatigue, Improves Muscle Strength and Quality of Life
|
D'Sa, S
|
|
2009
|
9 |
S1 |
p. S39-
1 p.
|
artikel
|
| 142 |
A291 Project CRAB: A Better Quality of Life Through an Early Diagnosis; Project of the Czech Myeloma Group
|
Straub, J
|
|
2009
|
9 |
S1 |
p. S48-S49
2 p.
|
artikel
|
| 143 |
A465 Project NEMY: Early Diagnostics, Prophylaxis and Treatment of Polyneuropathy in the Patients with MM
|
Spika, I
|
|
2009
|
9 |
S1 |
p. S74-
1 p.
|
artikel
|
| 144 |
A346 Prospective Study of Serum FLC and Other M-Protein Assays: When and How to Measure Response?
|
Drayson, MT
|
|
2009
|
9 |
S1 |
p. S56-
1 p.
|
artikel
|
| 145 |
A533 RAD001: Phase II Trial in Relapsed/Refractory Waldenström Macroglobulinemia, the DFCI Experience
|
Ghobrial, IM
|
|
2009
|
9 |
S1 |
p. S82-S83
2 p.
|
artikel
|
| 146 |
A343 Rapid Stimulation of Bone Formation by Bortezomib in Multiple Myeloma
|
Plesner, T
|
|
2009
|
9 |
S1 |
p. S55-
1 p.
|
artikel
|
| 147 |
A313 R2CdA in Waldenström (WM): Do Polymorphism and Gene Expression Have Predictive Roles in Response?
|
Rabascio, C
|
|
2009
|
9 |
S1 |
p. S50-
1 p.
|
artikel
|
| 148 |
A063 Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation in Myeloma: A Prospective Trial
|
Gahrton, G
|
|
2009
|
9 |
S1 |
p. S9-S10
2 p.
|
artikel
|
| 149 |
A366 Relevance of Conventional Prognostic Factors in Multiple Myeloma (MM) in the Era of Novel Therapies
|
Kapoor, P
|
|
2009
|
9 |
S1 |
p. S60-
1 p.
|
artikel
|
| 150 |
A616 Response to Thalidomide in Patients with MM Following Disease Progression with Pomalidomide
|
Mughal, T
|
|
2009
|
9 |
S1 |
p. S91-
1 p.
|
artikel
|
| 151 |
A139 Results of ASCT in 34 Patients with Amyloidosis from a Single Center
|
Cibeira, MT
|
|
2009
|
9 |
S1 |
p. S23-
1 p.
|
artikel
|
| 152 |
A007 Retreatment with Bortezomib in Multiple Myeloma
|
Kraj, MA
|
|
2009
|
9 |
S1 |
p. S4-
1 p.
|
artikel
|
| 153 |
A458 Retropective Comparison of Engraftment After First and Second Autotransplantations for Relapsed Myeloma
|
Winter, AJ
|
|
2009
|
9 |
S1 |
p. S74-
1 p.
|
artikel
|
| 154 |
A415 RIC allo-SCT for Patients with High-Risk Myeloma: A Survey from the SFGM-TC
|
Mohty, M
|
|
2009
|
9 |
S1 |
p. S65-
1 p.
|
artikel
|
| 155 |
A092 RMPT in Relapsed/Refractory Multiple Myeloma: Results of a Multicenter Phase II Clinical Trial
|
Palumbo, A
|
|
2009
|
9 |
S1 |
p. S14-S15
2 p.
|
artikel
|
| 156 |
A442 Role of Comorbidities in Multiple Myeloma Patients Receiving RIC Allograft
|
Farina, L
|
|
2009
|
9 |
S1 |
p. S71-
1 p.
|
artikel
|
| 157 |
A436 Role of Soluble Syndecan-1 in FLC Hypersecretion in MM
|
Maltezas, D
|
|
2009
|
9 |
S1 |
p. S70-
1 p.
|
artikel
|
| 158 |
A521 R/R MM: Efficacy of VTD + Liposomal Doxorubicin Is Unaffected by Previous Anthracycline/Bortezomib
|
Ciolli, SE
|
|
2009
|
9 |
S1 |
p. S81-
1 p.
|
artikel
|
| 159 |
A159 Safety and Efficacy of Bortezomib in Refractory/Relapsed Multiple Myeloma
|
Lalagianni, CE
|
|
2009
|
9 |
S1 |
p. S26-
1 p.
|
artikel
|
| 160 |
A236 Second Autologous Transplantation After Bortezomib-Based Re-Induction Therapy: The UK Experience
|
Morris, T
|
|
2009
|
9 |
S1 |
p. S40-S41
2 p.
|
artikel
|
| 161 |
A210 Sequential VAD and VTD Followed by ASCT and Maintenance with Bortezomib for Newly Diagnosed MM
|
Yoon, SS
|
|
2009
|
9 |
S1 |
p. S34-
1 p.
|
artikel
|
| 162 |
A351 Serum FLC Levels Can Be Reduced Rapidly; Lower Levels Are Associated with Renal Recovery
|
Drayson, MT
|
|
2009
|
9 |
S1 |
p. S57-S58
2 p.
|
artikel
|
| 163 |
A412 Serum Free-Immunoglobulin Light Chains Testing Is Frequently Abnormal in Patients with B-Cell Non-Hodgkin and Hodgkin Lymphoma and May Change in Value for Prognosis and Therapeutic Monitoring
|
De Filippi, R
|
|
2009
|
9 |
S1 |
p. S64-S65
2 p.
|
artikel
|
| 164 |
A189 Serum Free Light Chain Used with Electrophoresis Increases Sensitivity for Monoclonal Gammopathies
|
Holding, S
|
|
2009
|
9 |
S1 |
p. S33-
1 p.
|
artikel
|
| 165 |
A576 sFLC in Healthy Indian Subjects and Myeloma Patients
|
Kumar, R
|
|
2009
|
9 |
S1 |
p. S87-
1 p.
|
artikel
|
| 166 |
A424 sFLCR in LPL/WM Patients at Diagnosis
|
Tzenou, T
|
|
2009
|
9 |
S1 |
p. S67-
1 p.
|
artikel
|
| 167 |
A084 Similar Benefit in Patients Aged q 75 Years Versus < 75 Years with VMP in First-Line MM and Bortezomib in Relapsed MM
|
Kropff, M
|
|
2009
|
9 |
S1 |
p. S12-
1 p.
|
artikel
|
| 168 |
A474 Single-Agent Cytarabine Effectively Mobilizes Stem Cells in Heavily Pretreated Myeloma Patients
|
Stewart, OP
|
|
2009
|
9 |
S1 |
p. S75-S76
2 p.
|
artikel
|
| 169 |
A612 Six Years of Experience and Outcome with Maintenance Therapy with Very Low-Dose Thalidomide After AU
|
Mettivier, V
|
|
2009
|
9 |
S1 |
p. S91-
1 p.
|
artikel
|
| 170 |
A360 Skeletal Microstructural Changes in MGUS
|
Drake, MT
|
|
2009
|
9 |
S1 |
p. S59-
1 p.
|
artikel
|
| 171 |
A439 Solid Organ Transplantation in AL Amyloidosis: Lessons Learned and Its Current Role
|
Gibbs, SD
|
|
2009
|
9 |
S1 |
p. S71-
1 p.
|
artikel
|
| 172 |
A089 Solitary Plasmacytoma: A SEER Database Analysis of Survival
|
Ramsingh, G
|
|
2009
|
9 |
S1 |
p. S13-S14
2 p.
|
artikel
|
| 173 |
A394 Stem Cell Transplantation in Multiple Myeloma: One Center Experience
|
Maisnar, V
|
|
2009
|
9 |
S1 |
p. S63-S64
2 p.
|
artikel
|
| 174 |
A451 Superiority of VTD over TD Incorporated Into ASCT for Newly Diagnosed MM
|
Cavo, M
|
|
2009
|
9 |
S1 |
p. S73-
1 p.
|
artikel
|
| 175 |
A028 Superior Outcomes with Recent Treatments for Myeloma
|
Delasalle, KB
|
|
2009
|
9 |
S1 |
p. S6-
1 p.
|
artikel
|
| 176 |
A232 Superior Survival with VMP Versus MP After Longer Follow-up and Response to Subsequent Therapy in VISTA
|
San Miguel, J
|
|
2009
|
9 |
S1 |
p. S39-S40
2 p.
|
artikel
|
| 177 |
A619 Supportive Care Needs and Quality of Life in Patients with Multiple Myeloma and Their Partners
|
Cavet, J
|
|
2009
|
9 |
S1 |
p. S92-
1 p.
|
artikel
|
| 178 |
A222 Survival and Years of Life Lost in Different Age Categories of Patients with Multiple Myeloma
|
Ludwig, H
|
|
2009
|
9 |
S1 |
p. S37-
1 p.
|
artikel
|
| 179 |
A002 Synchronous GIST in a Patient with Multiple Myeloma Clinical studies including Transplanation
|
Kraj, MA
|
|
2009
|
9 |
S1 |
p. S3-
1 p.
|
artikel
|
| 180 |
A610 T-BiRD Therapy for Up-Front Use in Symptomatic Multiple Myeloma
|
Mark, TM
|
|
2009
|
9 |
S1 |
p. S90-
1 p.
|
artikel
|
| 181 |
A187 T-Cell Depleted RIC Allogeneic Stem Cells Transplantation: A Platform for Immunotherapy
|
Raymakers, R
|
|
2009
|
9 |
S1 |
p. S32-
1 p.
|
artikel
|
| 182 |
A053 ThaDD Versus ThaDD Plus HDT in Elderly Patients with de novo MM
|
Offidani, M
|
|
2009
|
9 |
S1 |
p. S9-
1 p.
|
artikel
|
| 183 |
A498 Thalidomide + Dexamethasone After ASCT Improves PFS in MM: A Brazilian Randomized Trial
|
Maiolino, A
|
|
2009
|
9 |
S1 |
p. S78-S79
2 p.
|
artikel
|
| 184 |
A174 Thalidomide/Dexamethasone Induction Therapy in Newly Diagnosed Myeloma Patients with Renal Failure
|
Tosi, P
|
|
2009
|
9 |
S1 |
p. S30-
1 p.
|
artikel
|
| 185 |
A160 Thalidomide/Dexamethasone (TD) Versus Bortezomib (Velcade)/Thalidomide/Dexamethasone (VTD) Versus VB
|
Rosiñol, L
|
|
2009
|
9 |
S1 |
p. S26-
1 p.
|
artikel
|
| 186 |
A067 Thalidomide/Dexamethasone (THALDEX) as Salvage Therapy for Multiple Myeloma Patients First Relapsing
|
Charlinski, G
|
|
2009
|
9 |
S1 |
p. S10-
1 p.
|
artikel
|
| 187 |
A147 Thalidomide/Interferon Versus Interferon Maintenance After Thal/Dex Versus MP
|
Ludwig, H
|
|
2009
|
9 |
S1 |
p. S24-S25
2 p.
|
artikel
|
| 188 |
A339 The Bone Marker ICTP Adds to the Prognostic Significance of the ISS in Symptomatic Multiple Myeloma
|
Jakob, C
|
|
2009
|
9 |
S1 |
p. S54-S55
2 p.
|
artikel
|
| 189 |
A285 The Dutch Lenalidomide Named Patient Program: Results and Feasibility in Heavily Pretreated Patients
|
Kneppers, E
|
|
2009
|
9 |
S1 |
p. S47-S48
2 p.
|
artikel
|
| 190 |
A502 The Impact of Age in the Long-Term Outcome of Patients with Newly Diagnosed Multiple Myeloma
|
Garcia, A
|
|
2009
|
9 |
S1 |
p. S79-
1 p.
|
artikel
|
| 191 |
A617 The Long-Term Use of Lenalidomide for the Management of Multiple Myeloma: Case-Based Studies
|
Mughal, T
|
|
2009
|
9 |
S1 |
p. S91-
1 p.
|
artikel
|
| 192 |
A161 The PAD (Ireland) Study for Patients with Refractory and Relapsed Myeloma: An Update
|
Morris, T
|
|
2009
|
9 |
S1 |
p. S27-
1 p.
|
artikel
|
| 193 |
A093 The Presence of Normal PC at Diagnosis by Flow Cytometry is a Favorable Prognostic Feature in MM
|
Paiva, BL
|
|
2009
|
9 |
S1 |
p. S15-
1 p.
|
artikel
|
| 194 |
A420 The Roles of Serum Free Light Chain Assay on The Prognosis of Multiple Myeloma
|
Watanaboonyongcharoen, P
|
|
2009
|
9 |
S1 |
p. S66-
1 p.
|
artikel
|
| 195 |
A182 The t(14;20)(q32;q12): A Rare Cytogenetic Change in Multiple Myeloma (MM) Associated with Poor Outcome
|
Vekemans, MC
|
|
2009
|
9 |
S1 |
p. S31-
1 p.
|
artikel
|
| 196 |
A453 Total Marrow Irradiation, Busulfan, and Cyclophosphamide Is Equivalent to Tandem Melphalan in Myeloma
|
Knop, S
|
|
2009
|
9 |
S1 |
p. S73-S74
2 p.
|
artikel
|
| 197 |
A188 Total Marrow Irradiation (TMI) as Part of Tandem Autotransplantation (TAT) for Multiple Myeloma
|
Somlo, G
|
|
2009
|
9 |
S1 |
p. S32-S33
2 p.
|
artikel
|
| 198 |
A164 Treatment-Related AML/MDS in Multiple Myeloma (MM)
|
Vadikoliou, C
|
|
2009
|
9 |
S1 |
p. S28-
1 p.
|
artikel
|
| 199 |
A508 Treatment Response and Survival in Myeloma Renal Failure
|
Behrens, J
|
|
2009
|
9 |
S1 |
p. S79-S80
2 p.
|
artikel
|
| 200 |
A532 Treatment Response and Survival in Myeloma Renal Failure
|
Behrens, J
|
|
2009
|
9 |
S1 |
p. S82-
1 p.
|
artikel
|
| 201 |
A298 Uncommon Cases of Extramedullary Plasmocytoma
|
Varoczy, L
|
|
2009
|
9 |
S1 |
p. S49-
1 p.
|
artikel
|
| 202 |
Author Index
|
|
|
2009
|
9 |
S1 |
p. S161-S168
8 p.
|
artikel
|
| 203 |
A123 Vaccination of Multiple Myeloma Patients with RNA-Electroporated Mature Dendritic Cells
|
Raymakers, R
|
|
2009
|
9 |
S1 |
p. S20-
1 p.
|
artikel
|
| 204 |
A085 VDE for Relapsed/Refractory Multiple Myeloma in Elderly Patients
|
Mele, G
|
|
2009
|
9 |
S1 |
p. S12-
1 p.
|
artikel
|
| 205 |
A166 VMP in Renally Impaired Newly Diagnosed MM Patients: Cohort Analysis of the VISTA Study
|
Dimopoulos, MA
|
|
2009
|
9 |
S1 |
p. S29-
1 p.
|
artikel
|
| 206 |
A246 VMP Results in Fewer Bone Events and Greater ALP Increases Versus MP in the VISTA Study in Front-Line MM
|
Delforge, M
|
|
2009
|
9 |
S1 |
p. S43-
1 p.
|
artikel
|
| 207 |
A242 Vorinostat and Bortezomib in Relapsed/Refractory MM
|
Weber, DM
|
|
2009
|
9 |
S1 |
p. S42-
1 p.
|
artikel
|
| 208 |
A306 Vorinostat + Bortezomib in Bortezomib-Refractory MM
|
Mazumder, A
|
|
2009
|
9 |
S1 |
p. S49-S50
2 p.
|
artikel
|
| 209 |
A239 Vorinostat/Lenalidomide/Dexamethasone: A Case Study
|
Siegel, DS
|
|
2009
|
9 |
S1 |
p. S41-
1 p.
|
artikel
|
| 210 |
A241 Vorinostat/Lenalidomide/Dexamethasone: A Phase I Study
|
Siegel, DS
|
|
2009
|
9 |
S1 |
p. S41-S42
2 p.
|
artikel
|
| 211 |
A248 Vorinostat plus Bortezomib in MM: A Phase I Study
|
Weber, DM
|
|
2009
|
9 |
S1 |
p. S44-
1 p.
|
artikel
|
| 212 |
A243 VTD Followed by MPT Demonstrates High Response Rates for High-Risk Patients with Multiple Myeloma
|
Eom, HS
|
|
2009
|
9 |
S1 |
p. S42-S43
2 p.
|
artikel
|
| 213 |
A482 What is the Best Maintenance Therapy for Multiple Myeloma
|
Mele, G
|
|
2009
|
9 |
S1 |
p. S77-
1 p.
|
artikel
|
| 214 |
A018 Whole-Body MRI in Asymptomatic Plasma Cell Disease
|
Hillengass, J
|
|
2009
|
9 |
S1 |
p. S6-
1 p.
|
artikel
|
| 215 |
B601 aCGH in Vk*MYC Mice Identifies Genetic Changes Shared with Human MM
|
Chesi, M
|
|
2009
|
9 |
S1 |
p. S157-S158
2 p.
|
artikel
|
| 216 |
B176 Acquisition of a Multidrug Resistant Phenotype with a Proteasome Inhibitor
|
Boise, LH
|
|
2009
|
9 |
S1 |
p. S107-S108
2 p.
|
artikel
|
| 217 |
B034 A Gene Expression—Based Proliferation Index as Independent Prognostic Factor in Multiple Myeloma
|
Hose, D
|
|
2009
|
9 |
S1 |
p. S98-
1 p.
|
artikel
|
| 218 |
B455 A Molecular Characterization of 17p Deletion in Myeloma, Related to Maintenance Thalidomide Outcome
|
Boyd, KD
|
|
2009
|
9 |
S1 |
p. S137-
1 p.
|
artikel
|
| 219 |
B203 A New Anti-Dkk-1 Antibody Targeting Myeloma Bone Disease
|
Pozzi, S
|
|
2009
|
9 |
S1 |
p. S111-
1 p.
|
artikel
|
| 220 |
B048 A New IAP Inhibitor Induces Apoptosis of Myeloma Cells and Synergizes with Antimyeloma Therapeutics
|
Khong, TF
|
|
2009
|
9 |
S1 |
p. S99-
1 p.
|
artikel
|
| 221 |
B050 Angiogenesis in Multiple Myeloma: Induction by Normal Plasma Cell — and Aberrantly Expressed Genes
|
Hose, D
|
|
2009
|
9 |
S1 |
p. S99-S100
2 p.
|
artikel
|
| 222 |
B202 A Novel Angiogenesis Model for Screening Antiangiogenic Compounds
|
Chen, H
|
|
2009
|
9 |
S1 |
p. S111-
1 p.
|
artikel
|
| 223 |
B551 A Novel Chemosensitivity Index for Chemotherapy Correlates to Resistance and Refractoriness
|
Johnsen, HE
|
|
2009
|
9 |
S1 |
p. S147-
1 p.
|
artikel
|
| 224 |
B587 A Novel Genetic Polymorphism in the DNA Polymerase Kappa Gene May Play a Role in Multiple Myeloma
|
Morse, HR
|
|
2009
|
9 |
S1 |
p. S154-S155
2 p.
|
artikel
|
| 225 |
B483 A Novel Small-Molecule Inhibitor RGB 286638 Induces Apoptosis and Necrosis in Multiple Myeloma
|
Cirstea, D
|
|
2009
|
9 |
S1 |
p. S139-S140
2 p.
|
artikel
|
| 226 |
B563 Anti-DKK1 mAb (BHQ880) as a Potential Therapeutic Agent for Multiple Myeloma
|
Fulciniti, M
|
|
2009
|
9 |
S1 |
p. S151-
1 p.
|
artikel
|
| 227 |
B599 Apoptosis-Inducing ICAM-1 Antibody BI-505 Is a Potent Inhibitor of Multiple Myeloma
|
Veitonmäki, NE
|
|
2009
|
9 |
S1 |
p. S157-
1 p.
|
artikel
|
| 228 |
B168 APRIL Induces Proliferation of Primary Myeloma Cells Expressing Cyclin D2
|
Quinn, JP
|
|
2009
|
9 |
S1 |
p. S106-S107
2 p.
|
artikel
|
| 229 |
B405 Association of Genetic Variants with FISH-Based Karyotyping Status in Multiple Myeloma Patients
|
Johnson, DC
|
|
2009
|
9 |
S1 |
p. S132-S133
2 p.
|
artikel
|
| 230 |
B457 AT7519, a Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma via GSK3B
|
Santo, L
|
|
2009
|
9 |
S1 |
p. S137-S138
2 p.
|
artikel
|
| 231 |
B033 Aurora-Kinase Inhibition for Tailored Risk-Adapted Treatment of Multiple Myeloma
|
Hose, D
|
|
2009
|
9 |
S1 |
p. S97-S98
2 p.
|
artikel
|
| 232 |
B341 BAY 73-4506, A Novel Orally Available Multikinase Inhibitor in MM
|
Breitkreutz, I
|
|
2009
|
9 |
S1 |
p. S125-
1 p.
|
artikel
|
| 233 |
B145 BMSC-induced Drug Resistance by Arresting MM Cells at First Contact
|
Menu, E
|
|
2009
|
9 |
S1 |
p. S104-S105
2 p.
|
artikel
|
| 234 |
B037 CAL-101: A Selective Inhibitor of PI3K p110D for the Treatment of Multiple Myeloma
|
Ikeda, H
|
|
2009
|
9 |
S1 |
p. S98-S99
2 p.
|
artikel
|
| 235 |
B500 CD32B Expression Reflects Intraclonal Functional Heterogeity in Multiple Myeloma
|
Comenzo, RL
|
|
2009
|
9 |
S1 |
p. S141-
1 p.
|
artikel
|
| 236 |
B570 Centrosomal Clustering: A Novel Therapeutic Target for Multiple Myeloma
|
Raab, MS
|
|
2009
|
9 |
S1 |
p. S153-
1 p.
|
artikel
|
| 237 |
B186 Changes in Glutathione Levels and Apoptotic Signaling Associated with Resistance to Arsenic Trioxide
|
Boise, LH
|
|
2009
|
9 |
S1 |
p. S109-
1 p.
|
artikel
|
| 238 |
B206 Characterization of Cancer Stem Cells in Multiple Myeloma
|
Sanchez, E
|
|
2009
|
9 |
S1 |
p. S112-
1 p.
|
artikel
|
| 239 |
B178 Chronic Administration of Carfilzomib in Experimental Animals Does Not Cause Neurotoxicity
|
Demo, SD
|
|
2009
|
9 |
S1 |
p. S108-
1 p.
|
artikel
|
| 240 |
B281 Ciliary Proteins and Hedgehog Pathway in Multiple Myeloma
|
Blotta, S
|
|
2009
|
9 |
S1 |
p. S120-
1 p.
|
artikel
|
| 241 |
B427 Combined Treatment of Bortezomib and VPA Synergistically Inhibited the Growth of MM Cells
|
Park, J
|
|
2009
|
9 |
S1 |
p. S134-
1 p.
|
artikel
|
| 242 |
B389 Comprehensive Analysis of the MET Protooncogene Promoter Regulation in Multiple Myeloma
|
Trzyna, E
|
|
2009
|
9 |
S1 |
p. S130-
1 p.
|
artikel
|
| 243 |
B026 CS1 Promotes Multiple Myeloma Cell Adhesion, Clonogenic Growth, and Tumorigenicity via c-Maf Mediation
|
Tai, YT
|
|
2009
|
9 |
S1 |
p. S96-S97
2 p.
|
artikel
|
| 244 |
B556 CXCR7 Regulates SDF-1 Induced, Adhesion, Homing, and Signaling in Multiple Myeloma
|
Burwick, N
|
|
2009
|
9 |
S1 |
p. S149-
1 p.
|
artikel
|
| 245 |
B234 Dasatinib and Dexamethasone Combination Therapy Targets Myeloma and the Tumor Microenvironment
|
Ramasamy, KA
|
|
2009
|
9 |
S1 |
p. S116-S117
2 p.
|
artikel
|
| 246 |
B409 Defective Stem Cell Mobilization in OCIF-Knockout Mice
|
Miwa, A
|
|
2009
|
9 |
S1 |
p. S133-
1 p.
|
artikel
|
| 247 |
B118 Del MAF(16q23) in (SE Thames) Myeloma Patients is Strongly Associated with Hyperdiploidy and del13q
|
Ladon, D
|
|
2009
|
9 |
S1 |
p. S103-
1 p.
|
artikel
|
| 248 |
B278 Development of a Whole-Cell Assay to Monitor Proteasome Activity in Multiple Myeloma
|
Liggett, A
|
|
2009
|
9 |
S1 |
p. S119-
1 p.
|
artikel
|
| 249 |
B054 Differential Pattern of CD4+ and CD8+ T-cell Immunity to MAGE-A1/-A2/-A3
|
Pratt, G
|
|
2009
|
9 |
S1 |
p. S100-
1 p.
|
artikel
|
| 250 |
B029 Dihydroorotate Dehydrogenase (DHODH) is a Promising Novel Target in the Treatment of Multiple Myeloma
|
Baumann, P
|
|
2009
|
9 |
S1 |
p. S97-
1 p.
|
artikel
|
| 251 |
B195 DNA DSBs Induction by Zalypsis, a Novel Marine Compound, Results in Potent Antimyeloma Activity
|
Ocio, EM
|
|
2009
|
9 |
S1 |
p. S109-S110
2 p.
|
artikel
|
| 252 |
B304 Does Toll-like Receptor 9 Signaling Play a Role in Myeloma Disease Progression?
|
Standal, T
|
|
2009
|
9 |
S1 |
p. S121-S122
2 p.
|
artikel
|
| 253 |
B565 Downregulation of Nuclear Receptor Corepressor 2 Enhances the Resistance Against Bortezomib in U26
|
Ahn, KS
|
|
2009
|
9 |
S1 |
p. S152-
1 p.
|
artikel
|
| 254 |
B403 DSG2, a Novel Key Player Regulating Cell Proliferation and Cell Cycle Progression in t(4;14) Myeloma
|
Brito, JL
|
|
2009
|
9 |
S1 |
p. S132-
1 p.
|
artikel
|
| 255 |
B528 Dual PI3K and mTOR Inhibition in Waldenström Macroglobulinemia
|
Husu, EN
|
|
2009
|
9 |
S1 |
p. S144-S145
2 p.
|
artikel
|
| 256 |
B012 Efficacy and Safety of Anti-b2M mAbs to Treat MM
|
Yang, J
|
|
2009
|
9 |
S1 |
p. S96-
1 p.
|
artikel
|
| 257 |
B205 Efficacy of CEP-18770 on Myeloma Growth
|
Chen, H
|
|
2009
|
9 |
S1 |
p. S112-
1 p.
|
artikel
|
| 258 |
B520 Efficacy of the Combination Therapy (ABCD) in Previously Treated Myeloma Patients
|
Di Raimondo, F
|
|
2009
|
9 |
S1 |
p. S143-
1 p.
|
artikel
|
| 259 |
B397 Expression of CTAs as Potential Targets for Immunotherapy Persists Following Treatment in MM
|
Van Duin, M
|
|
2009
|
9 |
S1 |
p. S131-
1 p.
|
artikel
|
| 260 |
B514 Expression of DKK1, HGF, FRP-B, and Syndecan1 in Bone Biopsies from MM Patients Correlates with OBD
|
Abildgaard, N
|
|
2009
|
9 |
S1 |
p. S142-
1 p.
|
artikel
|
| 261 |
B321 Familiarity of Multiple Myeloma and Macroglobulinemias
|
Ögmundsdóttir, HM
|
|
2009
|
9 |
S1 |
p. S123-
1 p.
|
artikel
|
| 262 |
B289 Farnesyltransferase Inhibitors are Synergistic with Bisphosphonates in Leading to Myeloma Cell Death
|
Günther, A
|
|
2009
|
9 |
S1 |
p. S121-
1 p.
|
artikel
|
| 263 |
B699 Farnesyltransferase Inhibitors Are Synergistic with Bisphosphonates in Leading to Myeloma Cell Death
|
Günther, A
|
|
2009
|
9 |
S1 |
p. S160-
1 p.
|
artikel
|
| 264 |
B127 FGFR3 Expression Is Important in the t(4;14)neg INA-6 HMCL
|
Vätsveen, TK
|
|
2009
|
9 |
S1 |
p. S103-
1 p.
|
artikel
|
| 265 |
B152 First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) vs. VAD as Induction Treatment Prior to High-dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)
|
Sonneveld, P
|
|
2009
|
9 |
S1 |
p. S105-S106
2 p.
|
artikel
|
| 266 |
B225 Free Light and Heavy/Light Chain Monitoring in IgGL Sera
|
Harding, SJ
|
|
2009
|
9 |
S1 |
p. S115-
1 p.
|
artikel
|
| 267 |
B373 Frequency of Abnormal Serum Free Light-Chain Ratio in a French Cohort of Patients with MGUS
|
Decaux, O
|
|
2009
|
9 |
S1 |
p. S128-S129
2 p.
|
artikel
|
| 268 |
B228 Gain 1q21 Versus Velcade- and Thalidomide-Based Regimens
|
Nemec, P
|
|
2009
|
9 |
S1 |
p. S116-
1 p.
|
artikel
|
| 269 |
B414 Genes MAGE-C1 and MAGE-A3 Are Central to the Survival and Chemotherapy-Resistance of Myeloma Cells
|
Luetkens, T
|
|
2009
|
9 |
S1 |
p. S133-S134
2 p.
|
artikel
|
| 270 |
B536 Gene Transcriptional Activity Analysis of the 6q Region in Waldenström Macroglobulinemia
|
Leleu, X
|
|
2009
|
9 |
S1 |
p. S145-
1 p.
|
artikel
|
| 271 |
B081 Hevylite™ Detects Residual IgGK in IgG Heavy-chain Disease
|
Harding, SJ
|
|
2009
|
9 |
S1 |
p. S100-S101
2 p.
|
artikel
|
| 272 |
B434 HGF Inhibited Osteoblatogenenesis Via Regulation of OPN Mediated MAPK and NF-kB Pathways in MM
|
Park, J
|
|
2009
|
9 |
S1 |
p. S134-S135
2 p.
|
artikel
|
| 273 |
B226 High HGF Levels are Associated with Response to Bortezomib
|
Svachova, H
|
|
2009
|
9 |
S1 |
p. S115-S116
2 p.
|
artikel
|
| 274 |
B461 HIV Protease Inhibitors Are Efficacious In Vivo in a Myeloma Mouse Model
|
Arnulf, B
|
|
2009
|
9 |
S1 |
p. S138-
1 p.
|
artikel
|
| 275 |
B104 IL-21 Induces Myeloma Cell Growth Via IGF-1 Autocrine Loop
|
Amiot, M
|
|
2009
|
9 |
S1 |
p. S102-
1 p.
|
artikel
|
| 276 |
B623 IL-17 Promotes Tumor cell Growth and Survival, and Inhibits Immune Function in Myeloma
|
Prabhala, RH
|
|
2009
|
9 |
S1 |
p. S159-
1 p.
|
artikel
|
| 277 |
B356 Imipramine Blue, a Tricyclic Compound and an Inhibitor of NADPH Oxidase Induces G2/M Cell-Cycle Arrest
|
David, E
|
|
2009
|
9 |
S1 |
p. S126-
1 p.
|
artikel
|
| 278 |
B325 Immune Dysregulation in MGUS: Evidence that MGUS Is Not an Immunologically Inert State
|
Feyler, S
|
|
2009
|
9 |
S1 |
p. S123-S124
2 p.
|
artikel
|
| 279 |
B157 Immunoglobulin Genes in IgG Versus IgA Multiple Myeloma
|
Agathangelidis, A
|
|
2009
|
9 |
S1 |
p. S106-
1 p.
|
artikel
|
| 280 |
B596 Immunoglobulin Ratios: An Alternative to Immunofixation
|
Harding, SJ
|
|
2009
|
9 |
S1 |
p. S156-S157
2 p.
|
artikel
|
| 281 |
B452 Impact of Lenalidomide on Bone Marrow Microenvironment: Implications for Stem Cell Mobilization
|
Lentzsch, S
|
|
2009
|
9 |
S1 |
p. S136-
1 p.
|
artikel
|
| 282 |
B562 Increasing Numbers of Most Mature Peripheral Blood B-Subsets are Observed in Monoclonal Gammopathies
|
Perez-Andres, M
|
|
2009
|
9 |
S1 |
p. S150-S151
2 p.
|
artikel
|
| 283 |
B591 Infectious RNA: A Novel Therapeutic Modality for Myeloma
|
Russell, SJ
|
|
2009
|
9 |
S1 |
p. S156-
1 p.
|
artikel
|
| 284 |
B553 In Silico Analysis of Global Gene Expression in Myeloma CCL: In Search of Stem Cell Genes
|
Johnsen, HE
|
|
2009
|
9 |
S1 |
p. S148-
1 p.
|
artikel
|
| 285 |
B213 Integrin-linked Kinase as a Target in Multiple Myeloma
|
Steinbrunn, TO
|
|
2009
|
9 |
S1 |
p. S113-S114
2 p.
|
artikel
|
| 286 |
B509 Integrin β7-Mediated Regulation of Multiple Myeloma Cell Adhesion, Proliferation, and Survival
|
Neri, P
|
|
2009
|
9 |
S1 |
p. S142-
1 p.
|
artikel
|
| 287 |
B207 In the Crosshairs: Targeting Myeloma CD28-B7 Interactions
|
Nair, JR
|
|
2009
|
9 |
S1 |
p. S112-S113
2 p.
|
artikel
|
| 288 |
B538 In Vivo Imaging Model of Multiple Myeloma and its Cellular Interaction with the Bone Marrow Milieu
|
Runnels, J
|
|
2009
|
9 |
S1 |
p. S145-S146
2 p.
|
artikel
|
| 289 |
B309 Lenalidomide Inhibits the Multiple Myeloma Cell Survival Factor IRF4/MUM1
|
Lopez-Girona, A
|
|
2009
|
9 |
S1 |
p. S122-
1 p.
|
artikel
|
| 290 |
B211 Lenalidomide Raises Low Regulatory T Cells in Myeloma
|
Quach, H
|
|
2009
|
9 |
S1 |
p. S113-
1 p.
|
artikel
|
| 291 |
B311 Lenalidomide Treatment Interferes with Ras/MAPK Activation and Induces Apoptosis in Multiple Myeloma
|
Lopez-Girona, A
|
|
2009
|
9 |
S1 |
p. S123-
1 p.
|
artikel
|
| 292 |
B507 Lethal and Bortezomib-Sensitizing Targets in Myeloma Identified by Genome-Scale RNAi Screening
|
Tiedemann, RE
|
|
2009
|
9 |
S1 |
p. S141-S142
2 p.
|
artikel
|
| 293 |
B454 Mcl-1 Fragment Mcl-1128-350 Induces Inhibition of Multiple Myeloma Cell Proliferation and Apoptosis
|
Podar, K
|
|
2009
|
9 |
S1 |
p. S137-
1 p.
|
artikel
|
| 294 |
B267 MEK/ERK and Mevalonate Pathways Inhibition in Multiple Myeloma
|
Ricciardi, MR
|
|
2009
|
9 |
S1 |
p. S118-S119
2 p.
|
artikel
|
| 295 |
B094 Melphalan, Prednisone and Lenalidomide: Kinetics of Hematologic Toxicity and Time to Event Results
|
Palumbo, A
|
|
2009
|
9 |
S1 |
p. S101-
1 p.
|
artikel
|
| 296 |
B589 Melphalan Produces an Osteoclast-Like Phenotype in MM Cell Lines and Exposes a MM “Stem Cell”
|
Morse, HR
|
|
2009
|
9 |
S1 |
p. S155-
1 p.
|
artikel
|
| 297 |
B561 MFC as Recommended by EMN Produces Prognostic Information: A Retrospective Analysis of 109 Patients
|
Johnsen, HE
|
|
2009
|
9 |
S1 |
p. S150-
1 p.
|
artikel
|
| 298 |
B354 MicroRNA Expression in the Biology, Prognosis, and Therapy of Waldenström Macroglobulinemia
|
Roccaro, AM
|
|
2009
|
9 |
S1 |
p. S126-
1 p.
|
artikel
|
| 299 |
B106 MicroRNA Expression Profiling in Multiple Myeloma: Correlation with Genetic Abnormalities
|
Gutiérrez, NC
|
|
2009
|
9 |
S1 |
p. S102-S103
2 p.
|
artikel
|
| 300 |
B581 MicroRNA Regulate Growth and Angiogenesis in Multiple Myeloma
|
Roccaro, AM
|
|
2009
|
9 |
S1 |
p. S153-S154
2 p.
|
artikel
|
| 301 |
B310 Molecular Classification of Myeloma Cell Lines Is Related to that of Patients with Myeloma
|
Moreaux, J
|
|
2009
|
9 |
S1 |
p. S122-
1 p.
|
artikel
|
| 302 |
B340 Molecular Classification of Newly Diagnosed MM Patients Included in a Prospective Phase III Trial
|
Broyl, A
|
|
2009
|
9 |
S1 |
p. S124-S125
2 p.
|
artikel
|
| 303 |
B365 Molecular Cytogenetic Analysis of Waldenström Macroglobulinemia in Korea
|
Bang, S-M
|
|
2009
|
9 |
S1 |
p. S127-S128
2 p.
|
artikel
|
| 304 |
B557 Molecular Pathogenesis of MGUS and Multiple Myeloma
|
Kuehl, WM
|
|
2009
|
9 |
S1 |
p. S149-
1 p.
|
artikel
|
| 305 |
B590 Myeloma Cells as Measles Virus Delivery Vehicles
|
Russell, SJ
|
|
2009
|
9 |
S1 |
p. S155-
1 p.
|
artikel
|
| 306 |
B446 NK Cell—Mediated Immunologic Responses Against Myeloma by B7-1(CD80)/IL-2 Immune Gene Therapy
|
Guven, H
|
|
2009
|
9 |
S1 |
p. S135-S136
2 p.
|
artikel
|
| 307 |
B516 NT-proBNP Levels in Myeloma Patients Without Evidence of Amyloidosis
|
Zojer, N
|
|
2009
|
9 |
S1 |
p. S142-S143
2 p.
|
artikel
|
| 308 |
B444 Opposing Effects of Dexamethasone on Lenalidomide Activity in Multiple Myeloma
|
Schafer, PH
|
|
2009
|
9 |
S1 |
p. S135-
1 p.
|
artikel
|
| 309 |
B577 Osteoclast Gene Expression Profiling in Multiple Myeloma
|
Moreaux, J
|
|
2009
|
9 |
S1 |
p. S153-
1 p.
|
artikel
|
| 310 |
B279 Panel of Potential Proteomic Biomarkers for Predicting Response to Thalidomide in Multiple Myeloma
|
Rajpal, R
|
|
2009
|
9 |
S1 |
p. S119-S120
2 p.
|
artikel
|
| 311 |
B416 Paraprotein Interference During Clinical Chemistry Analysis: 4 Case Reports
|
Radocha, J
|
|
2009
|
9 |
S1 |
p. S134-
1 p.
|
artikel
|
| 312 |
B497 Pathways Shared by t(4;14) and D13 positive MM Patients Impact Response to Velcade/Thalidomide/Dexamethasone
|
Terragna, C
|
|
2009
|
9 |
S1 |
p. S141-
1 p.
|
artikel
|
| 313 |
B372 Peripheral Neuropathy Associated with Administration of Proteasome Inhibitors Is Mechanism Based
|
Silverman, L
|
|
2009
|
9 |
S1 |
p. S128-
1 p.
|
artikel
|
| 314 |
B137 Pharmacogenetic Modeling for Prediction of Patient Outcomes in Myeloma
|
Van Ness, BG
|
|
2009
|
9 |
S1 |
p. S103-S104
2 p.
|
artikel
|
| 315 |
B290 Phenotype of Plasma Cells in Multiple Myeloma
|
Kovarova, L
|
|
2009
|
9 |
S1 |
p. S121-
1 p.
|
artikel
|
| 316 |
B526 PKC412, Small-Molecule Tyrosine Kinase Inhibitor, Regulates Survival in Waldenström Macroglobulinemia
|
Melhem, MR
|
|
2009
|
9 |
S1 |
p. S144-
1 p.
|
artikel
|
| 317 |
B171 Polymorphism of TNF-a Predicts Clinical Outcome in Multiple Myeloma Based on Thalidomide Regimens
|
Du, J
|
|
2009
|
9 |
S1 |
p. S107-
1 p.
|
artikel
|
| 318 |
B447 Pomalidomide Inhibits MM Proliferation In Vitro via Enhanced Expression of Tumor Suppressor Genes
|
Schafer, PH
|
|
2009
|
9 |
S1 |
p. S136-
1 p.
|
artikel
|
| 319 |
B214 Predisposing or Protective HLA Specificities Associated with the Development of Multiple Myeloma (MM)
|
Beksac, M
|
|
2009
|
9 |
S1 |
p. S114-
1 p.
|
artikel
|
| 320 |
B216 Probing the Stem Cell in the 5T33 Multiple Myeloma Model
|
Van Valckenborgh, E
|
|
2009
|
9 |
S1 |
p. S114-S115
2 p.
|
artikel
|
| 321 |
B555 Prognostic Value of Free and Heavy/Light Chain Analysis
|
Harding, SJ
|
|
2009
|
9 |
S1 |
p. S148-S149
2 p.
|
artikel
|
| 322 |
B408 Protective Role of CYP1A1*2A in the Development of Multiple Myeloma
|
Park, HK
|
|
2009
|
9 |
S1 |
p. S133-
1 p.
|
artikel
|
| 323 |
B480 Proteomic Alterations Caused by Treatment with Velcade, Doxorubicin, and Dexamethasone in Myeloma
|
Sreekumar, A
|
|
2009
|
9 |
S1 |
p. S139-
1 p.
|
artikel
|
| 324 |
B539 Proteomic Analysis of Multiple Myeloma Identifies Upregulation of the Novel Protein CRIK
|
Ngo, HT
|
|
2009
|
9 |
S1 |
p. S146-
1 p.
|
artikel
|
| 325 |
B073 Quantification of IgAK/IgAL in Monoclonal Gammopathies
|
Harding, SJ
|
|
2009
|
9 |
S1 |
p. S100-
1 p.
|
artikel
|
| 326 |
B101 Quantification of Polymerising Serum Free Light Chains
|
Harding, SJ
|
|
2009
|
9 |
S1 |
p. S101-S102
2 p.
|
artikel
|
| 327 |
B494 Quantitative Protein Expression-Based Classification of MM
|
Bahlis, NJ
|
|
2009
|
9 |
S1 |
p. S140-S141
2 p.
|
artikel
|
| 328 |
B197 Rapamycin and Dasatinib Combination Enhances Apoptosis in MM Through Downregulation of p-Akt
|
Guglielmelli, T
|
|
2009
|
9 |
S1 |
p. S110-
1 p.
|
artikel
|
| 329 |
B390 Rare IgH/14q32 Translocations in Multiple Myeloma
|
Michaux, LM
|
|
2009
|
9 |
S1 |
p. S130-
1 p.
|
artikel
|
| 330 |
B525 Regulation of Histone Deacetylase in Waldenström Macroglobulinemia
|
Jia, X
|
|
2009
|
9 |
S1 |
p. S143-S144
2 p.
|
artikel
|
| 331 |
B592 Retargeted Coxsackievirus A21 for Myeloma Therapy
|
Russell, SJ
|
|
2009
|
9 |
S1 |
p. S156-
1 p.
|
artikel
|
| 332 |
B622 Rho-A and Rac-1 GTPases in Multiple Myeloma
|
Azab, AK
|
|
2009
|
9 |
S1 |
p. S159-
1 p.
|
artikel
|
| 333 |
B490 Role and Regulation of the Heat Shock Proteins Hsp72 and Hsp73 in Multiple Myeloma
|
Chatterjee, M
|
|
2009
|
9 |
S1 |
p. S140-
1 p.
|
artikel
|
| 334 |
B148 Role of Bcl-2/Bik Complex in Myeloma Cell Apoptosis
|
Amiot, M
|
|
2009
|
9 |
S1 |
p. S105-
1 p.
|
artikel
|
| 335 |
B153 Serum and Urine Light Chains in AL Amyloidosis
|
Mead, GP
|
|
2009
|
9 |
S1 |
p. S106-
1 p.
|
artikel
|
| 336 |
B253 Serum DKK1 Levels in Multiple Myeloma
|
Heider, U
|
|
2009
|
9 |
S1 |
p. S117-
1 p.
|
artikel
|
| 337 |
B260 Serum IgG κ/IgG λ Measurements in Monoclonal Gammopathies
|
Margetts, CD
|
|
2009
|
9 |
S1 |
p. S118-
1 p.
|
artikel
|
| 338 |
B358 SF1126, A Novel PI3K Inhibitor Results in Downstream Inhibition of the PI3K Axis and Displays Sequen
|
David, E
|
|
2009
|
9 |
S1 |
p. S127-
1 p.
|
artikel
|
| 339 |
B350 SNS-032, a Potent and Selective CDK2, 7 and 9 Inhibitor, Demonstrates Preclinical Activity in Human Multiple Myeloma
|
David, E
|
|
2009
|
9 |
S1 |
p. S125-S126
2 p.
|
artikel
|
| 340 |
B387 Studies on c-Kit Protein Expression and c-KIT Gene in MM Patients
|
Guglielmelli, T
|
|
2009
|
9 |
S1 |
p. S129-S130
2 p.
|
artikel
|
| 341 |
B398 Suggestion of a Tool for Assessment of Plasma Cells in the Bone Marrow of Myeloma Patients
|
Park, HK
|
|
2009
|
9 |
S1 |
p. S131-S132
2 p.
|
artikel
|
| 342 |
B608 Syndecan-1 Mediates HGF/c-Met Endocytosis and Signaling in Myeloma Cells
|
Wader, KF
|
|
2009
|
9 |
S1 |
p. S158-
1 p.
|
artikel
|
| 343 |
B381 Synergistic Action of Heat-Shock Protein—90 Inhibitor NVP-AUY922 with Histone Deacetylase Inhibition
|
Kaiser, M
|
|
2009
|
9 |
S1 |
p. S129-
1 p.
|
artikel
|
| 344 |
B200 Targeted Drug Combinations in Poor Prognosis Multiple Myeloma: Therapeutic Implications
|
Bisping, GH
|
|
2009
|
9 |
S1 |
p. S110-S111
2 p.
|
artikel
|
| 345 |
B194 Targeting c-Myc—expressing Multiple Myeloma (MM) by Inhibiting Cyclin Dependent Kinase 1 (CDK1)
|
Trudel, SM
|
|
2009
|
9 |
S1 |
p. S109-
1 p.
|
artikel
|
| 346 |
B044 Targeting EXT-1 Demonstrates a Crucial Role for the HS Chains Decorating Syndecan-1 in MM Growth
|
Pals, ST
|
|
2009
|
9 |
S1 |
p. S99-
1 p.
|
artikel
|
| 347 |
B180 Targeting Glucose Consumption and Autophagy in Myeloma
|
Shanmugam, M
|
|
2009
|
9 |
S1 |
p. S108-
1 p.
|
artikel
|
| 348 |
B357 Targeting Myeloma Bone Disease via Activin A Inhibition
|
Vallet, S
|
|
2009
|
9 |
S1 |
p. S126-S127
2 p.
|
artikel
|
| 349 |
B569 Targeting the Sp1 Transcription Factor in Multiple Myeloma
|
Fulciniti, M
|
|
2009
|
9 |
S1 |
p. S152-
1 p.
|
artikel
|
| 350 |
B022 The Effect of Bortezomib on Myeloma Cell Line
|
Potacova, A
|
|
2009
|
9 |
S1 |
p. S96-
1 p.
|
artikel
|
| 351 |
B540 The Effect of Insulin-Like Growth Factor-1 in Waldenström Macroglobulinemia
|
Melhem, MR
|
|
2009
|
9 |
S1 |
p. S146-S147
2 p.
|
artikel
|
| 352 |
B144 The Effect of JNJ-26481585 in Murine Myeloma Models
|
Deleu, SI
|
|
2009
|
9 |
S1 |
p. S104-
1 p.
|
artikel
|
| 353 |
B552 The European Myeloma Stem Cell Network (MSCNET)
|
Johnsen, HE
|
|
2009
|
9 |
S1 |
p. S147-S148
2 p.
|
artikel
|
| 354 |
B391 The Evaluation of Free Light Chains Using the ELISA Method
|
Maisnar, V
|
|
2009
|
9 |
S1 |
p. S131-
1 p.
|
artikel
|
| 355 |
B558 The Mechanism Causing Light Chain-Only Multiple Myeloma
|
Ely, SA
|
|
2009
|
9 |
S1 |
p. S150-
1 p.
|
artikel
|
| 356 |
B265 The mTOR Pathway is Activated in a Subset of MM and Correlates with High B2-microglobulin
|
Guglielmelli, T
|
|
2009
|
9 |
S1 |
p. S118-
1 p.
|
artikel
|
| 357 |
B376 The Role of MicroRNAs in Dexamethasone Response and Glucocorticoid Resistance in Multiple Myeloma
|
Gunaratne, PH
|
|
2009
|
9 |
S1 |
p. S129-
1 p.
|
artikel
|
| 358 |
B615 The Role of RTK's in Waldenström Macroglobulinemia
|
Azab, F
|
|
2009
|
9 |
S1 |
p. S158-S159
2 p.
|
artikel
|
| 359 |
B527 The Tyrosine Kinase Src Regulates Adhesion and Survival in Waldenström Macroglobulinemia
|
Ngo, HT
|
|
2009
|
9 |
S1 |
p. S144-
1 p.
|
artikel
|
| 360 |
B545 Tracking the Stem Cell in Light Chain Myeloma
|
Pfeifer, S
|
|
2009
|
9 |
S1 |
p. S147-
1 p.
|
artikel
|
| 361 |
B331 Tyrosine Kinase Inhibition in MM? Efficacy of the Combination of Dasatinib/Bortezomib/Dexamethasone
|
de Queiroz Crusoe, E
|
|
2009
|
9 |
S1 |
p. S124-
1 p.
|
artikel
|
| 362 |
B469 Unraveling the Synergism of Nab-Rapamycin and Perifosine Combination in Multiple Myeloma
|
Cirstea, D
|
|
2009
|
9 |
S1 |
p. S138-S139
2 p.
|
artikel
|
| 363 |
B582 Unusual Monoclonal Gammopathies Detected in the Clinical Laboratory of a General Hospital
|
Cellier, CC
|
|
2009
|
9 |
S1 |
p. S154-
1 p.
|
artikel
|
| 364 |
B564 Various Growth Factors Regulate Mesenchymal Stem Cell Differentiation Derived Human Multiple Myeloma
|
Lee, C
|
|
2009
|
9 |
S1 |
p. S151-S152
2 p.
|
artikel
|
| 365 |
B598 Vesicular Stomatitis Viruses for Myeloma Therapy
|
Russell, SJ
|
|
2009
|
9 |
S1 |
p. S157-
1 p.
|
artikel
|
| 366 |
B257 Vorinostat in Combination with Other Anti-MM Agents
|
Mitsiades, C
|
|
2009
|
9 |
S1 |
p. S117-S118
2 p.
|
artikel
|
| 367 |
B491 YB-1 Is Associated with Progressive Disease and Mediates Survival and Drug Resistance in MM
|
Chatterjee, M
|
|
2009
|
9 |
S1 |
p. S140-
1 p.
|
artikel
|
| 368 |
Multiple Myeloma: Biologic Understanding and Curative Outcome — Pushing the Envelope
|
Munshi, Nikhil C.
|
|
2009
|
9 |
S1 |
p. S2-
1 p.
|
artikel
|
Tijdschrift beschrijving